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ABSTRACT
Background Stent- assisted coiling of wide- necked 
intracranial aneurysms (IAs) using the Neuroform Atlas 
Stent System (Atlas) has shown promising results.
Objective To present the primary efficacy and safety 
results of the ATLAS Investigational Device Exemption 
(IDE) trial in a cohort of patients with posterior 
circulation IAs.
Methods The ATLAS trial is a prospective, multicenter, 
single- arm, open- label study of unruptured, wide- necked, 
IAs treated with the Atlas stent and adjunctive coiling. 
This study reports the results of patients with posterior 
circulation IAs. The primary efficacy endpoint was complete 
aneurysm occlusion (Raymond- Roy (RR) class I) on 
12- month angiography, in the absence of re- treatment or 
parent artery stenosis >50%. The primary safety endpoint 
was any major ipsilateral stroke or neurological death 
within 12 months. Adjudication of the primary endpoints 
was performed by an imaging core laboratory and a Clinical 
Events Committee.
Results The ATLAS trial enrolled and treated 116 patients at 
25 medical centers with unruptured, wide- necked, posterior 
circulation IAs (mean age 60.2±10.5 years, 81.0% (94/116) 
female). Stents were placed in all patients with 100% 
technical success rate. A total of 95/116 (81.9%) patients 
had complete angiographic follow- up at 12 months, of 
whom 81 (85.3%) had complete aneurysm occlusion (RR 
class I). The primary effectiveness outcome was achieved in 
76.7% (95% CI 67.0% to 86.5%) of patients. Overall, major 
ipsilateral stroke and secondary persistent neurological deficit 
occurred in 4.3% (5/116) and 1.7% (2/116) of patients, 
respectively.
Conclusions In the ATLAS IDE posterior circulation cohort, 
the Neuroform Atlas Stent System with adjunctive coiling 
demonstrated high rates of technical and safety performance.
Trial registration number https:// clinicaltrials. gov/ ct2/ 
show/ NCT02340585.
INTRODUCTION
Wide- necked intracranial aneurysms (IAs) (neck 
≥4 mm, dome- to- neck ratio <2) constitute at least 
40% of all IAs,1–3 and are difficult to treat with 
endovascular coiling alone given the propensity 
for coils to herniate into the parent artery.4 5 Stent- 
assisted coiling (SAC) is a well- established endovas-
cular treatment,6–9 which reconstructs the aneurysm 
neck, prevents coil herniation into the parent artery, 
and theoretically expedites aneurysm healing by 
creating a scaffold for endothelial coverage.5 10
The Neuroform stent system (Stryker Neurovas-
cular, Fremont, California, USA) was first approved 
by the United States Food and Drug Administra-
tion (FDA) in 2002. Since then, newer stent itera-
tions, such as Neuroform EX and EZ3, have been 
approved. The Neuroform Atlas Stent System 
(Atlas) is the newest generation.9 11–13 The device 
was designed to scaffold the aneurysm neck and 
support the placement of detachable, intrasaccular 
coils. Significant design advances include improved 
trackability and a smaller cell size, which provides 
better coil retention within the aneurysm. The Atlas 
stent design also allows for its delivery via a lower 
profile, 0.0165 inch (internal diameter) microcath-
eter as compared with the 0.027 inch microcatheter 
required for the original Neuroform stent. Finally, 
the new hybrid cell design, with closed cells at the 
proximal end, improves recrossing and enhances 
stability within the vessel, while the classic central 
open- cell design provides excellent wall apposition, 
conformability, and flexibility.
In a previous prospective Neuroform Atlas 
investigational device exemption (IDE) study of 
182 patients with anterior circulation IAs, SAC 
via the Atlas stent demonstrated high rates of 
complete occlusion at the 12- month angiographic 
follow- up,14 15 as well as promising safety profiles 
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we present the primary efficacy and safety results of the ATLAS 
IDE trial in a cohort of patients with posterior circulation IAs.
METHODS
Study design
The ATLAS IDE trial is a prospective, multicenter, open- label, 
non- randomized, two- cohort, single- arm study that enrolled 
patients with wide- necked intracranial saccular aneurysms to 
be treated with SAC using the Atlas stent at 25 medical centers 
in the USA. Safety and efficacy endpoints were evaluated in a 
modified intention- to- treat cohort of patients who signed the 
informed consent form and in whom the investigational device 
entered the body. An imaging core laboratory and an indepen-
dent Clinical Events Committee (CEC) adjudicated the primary 
efficacy and safety endpoints, respectively, to ensure consistency 
and accuracy of the data and minimize bias.
The institutional review board at each enrollment center 
approved the study protocol. Each patient completed a written 
informed consent prior to participation in the trial. All data were 
entered into a Health Insurance Portability and Accountability 
Act (HIPAA)- compliant electronic data capture system and 
monitored by the sponsor and a contract research organization. 
The data used to support the conclusions of this trial will be 
furnished, on reasonable requests, by the corresponding author.
Patient enrollment
Enrollment for patients with posterior circulation IAs (including 
vertebral, basilar, and posterior cerebral arteries) took place 
between June 2015 and December 2017. Clinical investiga-
tors and designated research staff at each center managed 
patient identification, recruitment, and enrollment. Patients 
were considered enrolled in the study once the site investigator 
determined that they met all trial inclusion/exclusion criteria 
and provided the signed informed consent form. The full study 
enrollment criteria are provided in online supplemental table 1). 
Briefly, patients were included if they were 18–80 years old and 
had a documented, wide- necked (neck ≥4 mm or dome- to- neck 
ratio <2), intracranial, saccular aneurysm arising from a parent 
vessel with a diameter of 2.0–4.5 mm. The following criteria 
were used to determine study exclusion: multiple untreated IAs 
requiring treatment, acute target aneurysm rupture <14 days 
prior to study treatment, modified Rankin Scale (mRS) score of 
≥4 or Hunt and Hess scale score ≥3, intracranial mass or cere-
bral vascular malformation, a target aneurysm in the anterior 
circulation proximal to the superior hypophyseal internal carotid 
artery, previous treatment with SAC embolization, a known 
absolute contraindication to angiography or antiplatelet therapy, 
Moyamoya disease, or underlying parent artery atherosclerosis.
Procedure description
The procedure was previously described in detail in the primary 
results of the ATLAS humanitarian device exemption study.16 In 
brief, all patients undergoing treatment were premedicated with 
dual antiplatelet therapy (aspirin and clopidogrel) for at least 
5 days. Platelet reactivity testing was not mandated. All proce-
dures were performed under general anesthesia, and anticoag-
ulation was managed according to each study site standard of 
care with a recommended activated clotting time of 250–300 
s during the procedure. Atlas was deployed using an Excelsior 
SL-10 or XT-17 (Stryker Neurovascular, Fremont, California, 
USA) microcatheter via a transfemoral, radial, or brachial percu-
taneous approach. Dual antiplatelet therapy was maintained for 
at least 3 months following stent implantation.
Follow-up evaluation
After the implant procedure, all treated patients had follow- up 
evaluations within 72 hours of the procedure, prior to hospital 
discharge, and at 2, 6, and 12 months. Data were collected 
to assess primary and secondary endpoints. Data consisted of 
neurological assessments (National Institutes of Health Stroke 
Scale (NIHSS), mRS), antiplatelet medication, and quality- of- life 
assessment (EQ- 5D- 3L)). Hunt and Hess scores were recorded 
for patients who had evidence of aneurysm rupture and subarach-
noid hemorrhage (SAH). Digital subtraction angiography (DSA) 
was performed at 12 months to evaluate the grade of aneurysm 
occlusion and parent vessel stenosis.
Primary efficacy outcome
The primary efficacy endpoint was complete aneurysm occlusion 
(defined as 100% occlusion of the aneurysm or Raymond- Roy 
(RR) class I)14 15 at 12- month follow- up DSA, in the absence of 
re- treatment or parent artery stenosis (>50%). Angiographic 
occlusion was assessed by an independent imaging core labo-
ratory, blinded to assessments made by the clinical sites, to 
avoid bias. The University of California San Francisco (UCSF) 
interventional radiology core laboratory provided angiographic 
evaluation of anonymized patients in the ATLAS trial. For this 
specific project, the angiogram reader was SWH, who has over 
15 years' experience in the interpretation of cerebral angiograms 
and the endovascular treatment of brain aneurysms.
Primary safety outcome
The primary safety endpoint was any incidence of major ipsi-
lateral stroke, defined as an ipsilateral stroke with an increase 
of four or more points on the NIHSS assessment at 24 hours 
after symptoms' onset, or neurological death within 12 months 
postprocedure. An independent CEC adjudicated prespecified 
primary endpoint events and serious device- related events. 
The threshold for the primary safety endpoint event rate was 
set at <25% for the posterior circulation cohort in the ATLAS 
trial, which was established after reviewing data extracted from 
the MAPS trial3 wide- necked aneurysm patient cohort as well 
as published rates of procedural and long- term morbidity and 
mortality.
Secondary outcomes
Secondary efficacy endpoints were assessed after the index 
procedure through 12 months, and included procedural tech-
nical success (defined as the proportion of patients in whom the 
Atlas stent was successfully delivered and deployed at the target 
location), rates of target aneurysm occlusion across RR classes, 
re- treatment, recanalization, progressive occlusion of the target 
aneurysm, incidence of parent artery stenosis (>50% stenosis), 
and stent migration.
Secondary safety endpoints were any serious adverse events 
(SAEs) through 12 months following the procedure, including 
any incidence of new or worsening major ipsilateral stroke as 
measured by the NIHSS, device- related SAE, target aneurysm 
rupture, and SAH.
Statistical analysis
Descriptive statistics were compiled for baseline variables, 
procedural characteristics, and endpoints. Continuous and 
ordinal variables are summarized as mean (SD), median, and 
IQR. Median and interquartile range are reported when distri-
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Percentages and numerators, denominators are presented for 
categorical and binary variables.
The proportion of patients who met the primary endpoints 
were compared with performance goals using the one- sided Fish-
er’s exact test with a significance level of α=0.025. The perfor-
mance goals were determined a priori based on a meta- analysis 
as well as regulatory and medical considerations. Analyses for 
posterior circulation cohorts were performed by constructing 
two- sided, 95% confidence intervals about the estimates of the 
percentage of patients with complete aneurysm occlusion and the 
percentage of patients experiencing a major ipsilateral stroke or 
neurological death using the exact binomial (Clopper- Pearson) 
method. Success in the posterior circulation cohort occurred 
when the lower bound of the efficacy endpoint was above 50% 
and the upper bound of the safety endpoint was below 25%. 
Missing values are imputed. All analyses were performed using 
SAS software, version 9.4 (SAS Institute Inc., Cary, North Caro-
lina, USA).
RESULTS
A total of 124 patients with posterior circulation IAs were 
initially enrolled across 25 US centers. The modified intention- 
to- treat cohort included 93.5% (116/124) after the exclusion of 
eight patients (online supplemental figure 1). Mean patient age 
was 60.2±10.5 years, 81.0% (94/116) were female, and 91.4% 
(106/116) were Caucasian (table 1). The most frequent comor-
bidities were hypertension (67.2%; 78/116) and hyperlipidemia 
(49.1%; 57/116). The majority of patients were either current 
smokers (40.5%; 47/116) or past smokers (38.8%; 45/116). A 
history of previous hemorrhagic stroke or multiple aneurysms 
was reported by 17.2% (20/116) and 17.2% (20/116) of patients, 
respectively. A total of 113 patients (97.4%) had a baseline mRS 
score ≤2. Thirteen patients (11.2%) had experienced previous 
rupture of their target aneurysms, of whom 10 were treated 
with coiling only, while two were treated with balloon- assisted 
coiling. The other patient with a previously ruptured target aneu-
rysm was untreated. The mean and median time from aneurysm 
rupture to stent placement was 800 and 189 days, respectively.
Target aneurysm characteristics are summarized in table 1.
Intraprocedural and postprocedural results
All procedures were technically successful (100.0%; 116/116). 
Patients were implanted with one (65.5%; 76/116) or two 
(34.5%; 40/116) Atlas stents. Multi- stent constructs were 
preplanned. Stents were implanted successfully in 94.5% 
(156/165) of attempts. Nine device failures occurred among five 
patients. All cases involved inadvertent deployment in the cath-
eter hub (seven) or the feeling of excess friction as the stent was 
advanced in the microcatheter requiring removal of the catheter. 
None of these stents was actually deployed in a patient and all 
cases were successfully completed with additional devices. The 
median procedure duration first puncture to wound closure 
was 109.0 min (IQR 85.0–140.0). Immediately postprocedure, 
complete occlusion (RR I) was achieved in 77.6% (90/116) 
of patients, residual aneurysm neck filling (RR II) in 19.0% 
(22/116), and residual aneurysm dome filling (RR III) in 3.4% 
(4/116).
Primary endpoints
Of the 116 patients who completed the 12- month follow- up, 95 
patients had DSA results available (table 2). The primary efficacy 
endpoint was achieved in 76.7% (95% CI 67.0% to 86.5%) of 
patients (p<0.001 vs performance goal, missing values handled 
with multiple imputation). The rate of complete occlusion, 
according to the imaging core laboratory, was 85.3% (81/95, 
95% CI 76.5% to 91.7%), while parent artery stenosis >50% 
occurred in 2.1% (2/95, 95% CI 0.3% to 7.4%) of patients. The 
rate of re- treatment was 7.8% (9/116, 95% CI 3.6% to 14.2%). 
Of the nine patients who underwent re- treatment, 2.6% (3/116) 
had complete occlusion postprocedure but recanalized, 0.9% 
(1/116) had preplanned staged procedures (achieved complete 
occlusion after stage 2 operation), 2.6% (3/116) had residual 
neck, and 1.7% (2/116) had residual aneurysm that persisted on 
follow- up imaging.
The incidence of the primary safety endpoint (major ipsilat-
eral stroke and/or neurological death) for all 116 patients was 
4.3% (5/116, 95% CI 1.4% to 9.8%, p<0.001; table 2). Major 






  Age 60.2±10.5
  Female 81.0% (94)
  White 91.4% (106)
Target aneurysm characteristics (site- reported)
  Aneurysm neck width (mm) 4.7±1.7
  Aneurysm size (mm) 7.1±3.0
  Dome:neck ratio 1.2±0.3
  Parent vessel diameter proximal to the aneurysm neck (mm) 2.9±0.6
  Parent vessel diameter distal to the aneurysm neck (mm) 2.4±0.5
Target aneurysm location
  Arising from the mid aspect of the PComA 1 (0.9%)
  Basilar apex 88 (75.9%)
  Basilar trunk 7 (6.0%)
  Superior cerebellar artery 5 (4.3%)
  Posterior inferior cerebellar artery 5 (4.3%)
  Vertebral artery 5 (4.3%)
  Vertebrobasilar junction 2 (1.7%)
  Other* 3 (2.6%)
Data are mean±SD, or n (%).
*Persistent trigeminal artery, fetal posterior cerebral artery, and posterior cerebral 
artery.
ATLAS, Assessment of Treatment with Lisinopril and Survival ; PComA, posterior 
communicating artery.
Table 2 Primary safety and efficacy endpoint rate through 12- month' 









Primary efficacy endpoint† 76.7% (67.0% to 
86.5%)
50% <0.001
Primary safety endpoint 5 (4.3%) (1.4% to 9.8%) 25% <0.001
  Major ipsilateral stroke 4 (3.4%) (0.9% to 8.6%)
  Neurologic death 1 (0.9%) (0.0% to 4.7%)
*One- sided binomial exact test of success against the performance goal at 12 
months (α=0.025).
†Multiple imputation for missing data.
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ipsilateral stroke occurred in 3.4% (4/116, 95% CI 0.9% to 
8.6%) of patients, while neurological death occurred in 0.9% 
(1/116, 95% CI 0.0% to 4.7%) of patients. This neurological 
death was the result of subdural hematoma and related severe 
pneumonia aspiration after experiencing a fall 75 days post-
procedure. Of the five patients who experienced unfavorable 
primary safety outcomes, 1.7% (2/116) recovered with no 
residual deficit on subsequent follow- up,
Secondary efficacy endpoints
Secondary endpoints were evaluated at the 12- month follow- up 
DSA (table 3). The majority of the 95 patients with available 
DSA results had RR I occlusion of the target aneurysm at a rate 
of 85.3% (81/95, 95% CI 76.5% to 91.7%). The rate of RR 
II occlusion of the target aneurysm was 9.5% (9/95, 95% CI 
4.4% to 17.2%), and for RR III was 5.3% (5/95, 95% CI 1.7% 
to 11.9%). Ninety of the 95 subjects had combined RR I and II 
(94.7%, 95% CI 88.1% to 98.3%).
Most patients had the same (71.6%; 68/95, 95% CI 61.4% to 
80.4%) or improved (17.9%; 17/95, 95% CI 10.8% to 27.1%) 
occlusion status of their target aneurysms compared with imme-
diate postprocedure RR scores. Only 10.5% (10/95, 95% CI 
5.2% to 18.5%) of patients had worse occlusion status compared 
with immediate postprocedure RR scores. For clinical outcome 
at 12 months' follow- up, 93.1% (95/102) of patients had an mRS 
score of 0–1, while 96.1% (98/102) had an mRS score of 0–2. 
There was no reported occurrence of stent migration (0.0%; 
0/95, 95% CI 0.0% to 3.8%).
Secondary safety endpoints
According to CEC adjudication, four patients experienced new 
or worsening major ipsilateral stroke (table 4), and these four 
patients were the same subjects who experienced the primary 
safety endpoint of major ipsilateral stroke. Two patients experi-
enced SAH: one patient experienced only SAH, while the other 
experienced both SAH and aneurysm rupture, although neither 
were related to stent placement. The patient who had both 
SAH and aneurysm rupture also had major ipsilateral stroke 
and was one of the patients who experienced the primary safety 
endpoint of major ipsilateral stroke. Clinically, the two patients 
who experienced either SAH alone or both SAH and aneurysm 
rupture returned for their 12- month visit and their mRS score 
was 0. All SAEs that were site- reported as ‘possibly’, ‘probably’, 
or ‘related’ to the study device were classified as ‘site- reported 
device- related SAEs’. This included 12 SAEs in 11 subjects. For 
two subjects, the events were also CEC- adjudicated as primary 
safety endpoint events (ie, major ipsilateral stroke). Four of 
the 11 subjects experienced site- reported device- related SAEs 
that were CEC- adjudicated as minor ischemic strokes. All four 
subjects had excellent long- term outcomes with mRS scores of 0 
or 1 and NIHSS scores of 0 at their 6- and 12- month follow- up 
visits. Five of the 11 subjects experienced site- reported device- 
related SAEs that were CEC- adjudicated as not strokes (of any 
type), SAH, or aneurysm rupture. Three of these patients had 
target aneurysm re- treatment based on asymptomatic recanali-
zation detected on routine follow- up imaging. Two of the five 
subjects had transient ischemic attacks, which occurred on post-
operative days 45 and 113, respectively.
DISCUSSION
The ATLAS IDE study included a cohort of 116 patients with wide- 
necked IAs located in the posterior circulation, making it the largest 
study using Atlas stents for this particular cohort of patients. In this 
study, SAC using Atlas was associated with excellent technical success 
and safety profile rates. Atlas SAC embolization provided a high rate 
of 12- month complete occlusion without stenosis or re- treatment 
in the majority of patients, with low incidence of safety endpoints. 
Therefore, Atlas SAC embolization successfully met both the effi-
cacy and safety endpoints of the trial, indicating that Atlas represents 
an efficacious and safe treatment option for SAC embolization of 
wide- necked IAs in the posterior cerebral circulation. Based on these 
results, the FDA awarded specific approval for use of Atlas stents in 
the posterior circulation on July 30, 2020, making it the only adjunc-
tive stent in the USA that has shown safety and effectiveness in the 
posterior neurovasculature.
Several meta- analyses of patients with wide- necked aneu-
rysms who underwent SAC treatment in the anterior or posterior 




Procedural technical success (per patient) 116/116 (100.0%)
  Subjects with one stent implanted 76/116 (65.5%)
  Subjects with two stents implanted 40/116 (34.5%)
Raymond- Roy class (core laboratory)
  I 81/95 (85.3%) (76.5% to 91.7%)
  II 9/95 (9.5%) (4.4% to 17.2%)
  III 5/95 (5.3%) (1.7% to 11.9%)
  1 and 2 combined 90/95 (94.7%) (88.1% to 98.3%)
Recanalization (1) 9/97 (9.3%) (4.3% to 16.9%)
Any Raymond- Roy class change over time 
(core laboratory)
  Same 68/95 (71.6%) (61.4% to 80.4%)
  Better 17/95 (17.9%) (10.8% to 27.1%)
  Worse 10/95 (10.5%) (5.2% to 18.5%)
Parent artery stenosis >50% (core 
laboratory)
2/95 (2.1%) (0.3% to 7.4%)
Incidence of stent migration (core 
laboratory)
0/95 (0.0%) (0.0% to 3.8%)
Incidence of re- treatment (site- reported) 9/116 (7.8%) (3.6% to 14.2%)
Data are n (%).
*Recanalization is defined as Raymond score of 3 at 12 month visit or retreatment 
due to recanalization.




New or worsening major ipsilateral 
stroke (CEC- adjudicated)
4 (3.4%) (0.9% to 8.6%)
Subarachnoid hemorrhage (CEC- 
adjudicated)*
2 (1.7%) (0.2% to 6.1%)
Aneurysm rupture (CEC- adjudicated)* 1 (0.9%) (0.0% to 4.7%)
Device- related serious adverse event 
(site- reported)
11 (9.5%) (4.8% to 16.3%)
Data are n (%).
*One subject experienced a serious adverse effect (SAE) on postoperative day 1 
that was site- reported as ‘vessel dissection related to subarachnoid hemorrhage 
(SAH)’ and possibly related to the device and was CEC- adjudicated as a major 
ipsilateral stroke, aneurysm rupture, and SAH’. This single event is therefore 
captured in four separate secondary endpoint categories (ie, new or worsening 
ipsilateral stroke, SAH, aneurysm rupture, and device- related SAE).
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circulation have been published.17–19 The results of these studies 
suggest that stenting wide- necked aneurysms with earlier generation 
stents can result in RR I occlusion rates in the range of 69–73%, with 
mortality rates less than 2.5%. Recanalization rates ranged from 9% 
to 13%, and one analysis reported an aggregate re- treatment rate 
of 5.7%.19 The results of our study demonstrate that treatment of 
wide- necked aneurysms with the Atlas stent results in comparable or 
improved outcomes compared with earlier generation stents.
Few studies have assessed efficacy and safety outcomes specific to 
the Atlas stent in wide- necked IAs. A recent retrospective analysis of a 
prospectively maintained database of 113 patients with wide- necked 
IAs in the anterior and posterior circulation reported a technical 
success rate of 100%.20 Complete occlusion (RR I) was achieved 
in 88% and 82% of patients immediately postprocedure and at the 
12- month follow- up, respectively. At the 6- month follow- up, 96.5% 
(109/113) of patients had an mRS score of 0–1, with a mortality 
rate of 2.7% (3/113) mostly due to SAH, and a morbidity rate of 
0.85%.20 Another retrospective study of 37 patients at three centers 
using the Atlas stent also demonstrated a technical success rate of 
100%. Complete occlusion (RR I was achieved in 83.8% (31/37) 
and 80.8% (21/26) immediately postprocedure and at the 6- month 
follow- up, respectively, while neurological morbidity was reported 
in 2.7% (1/37) of patients at the 6- month follow- up.13 Tsai et al 
reported their 1- year results using Atlas stent- assisted coil emboliza-
tion, which examined the efficacy and safety outcomes at discharge 
of 58 patients with 76 Atlas stents. In that retrospective study, 40 
patients were treated with a single stent, 15 with a Y- stent, and three 
with an X- stent configuration.21 The immediate RR I occlusion rate 
was 70.7% (41/58), with no neurological morbidity and an mRS 
score of 0 (IQR 0–1).21 These studies were retrospective in nature, 
used low to moderate numbers of patients,13 21 22 did not collect long- 
term follow- up data,21 and included heterogeneous IAs with respect 
to status, size, and location. The ATLAS IDE of wide- necked IAs in 
the posterior circulation has examined many of these limitations, and 
the results are specific to the posterior circulation.
The Low- profile Visualized Intraluminal Support (LVIS and LVIS 
Jr) stents (MicroVention, Aliso Viejo, California, USA) were the first 
neurovascular stents approved for SAC embolization of anterior 
circulation IAs in the USA. The efficacy and safety results for the 
Atlas stent were similar to those of the US LVIS pivotal multicenter 
trial of 153 patients with wide- necked IAs in the anterior and poste-
rior circulation at 12 months.23 Direct comparisons are difficult, but 
a recent study compared Atlas (37 patients) and LVIS Jr (27 patients) 
stent- assisted aneurysm coiling, after controlling for location, size, 
coiling technique, and coil packing density.12 That study observed 
greater rates of complete occlusion (RR I) with Atlas than with LVIS 
Jr (57% vs 41%), and this difference remained at follow- up (12.7 
months; 100% vs 81% (17/21)). The study also detected a signifi-
cantly lower rate of in- stent restenosis with Atlas (0% vs 19% (4/21)) 
along with similar re- treatment rates (0%).12
Limitations
The main limitation of ATLAS IDE is the single- arm nature of the 
study; thus, there was no direct comparative analysis with another 
aneurysm treatment device. However, this study had a relatively 
large sample size, and the study characteristics, including the inde-
pendent core laboratory, CEC, and prospective study design, were 
all meant to mitigate potential bias.
SUMMARY
In the ATLAS IDE posterior circulation study, Atlas SAC embolization 
demonstrated excellent technical success as well as promising effi-
cacy and safety profiles in patients with wide- necked IAs in the poste-
rior circulation. This was shown by the high rates of angiographic 
complete occlusion of IAs at 12 months and the low rates of serious 
neurological events and mortality. Therefore, the Neuroform Atlas 
Stent System is an effective and safe treatment option for patients 
with wide- necked, posterior circulation IAs.
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